



#15/K.T.
4/13
ELECT.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents

Washington, D.C. 20231 on March 20, 2003.

David Saliwanchik

David R. Saliwanchik, Patent Attorney

ELECTION UNDER 35 USC §121
Examining Group 1635
Patent Application
Docket No. SPO-113
Serial No. 09/763,586

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAR 31 2003

TECH CENTER 1600/2900

Examiner : J. Douglas Schultz, Ph.D.
Art Unit : 1635
Applicants : Kenji Kadomatsu, Mitsuru Horiba, Takashi Muramatsu, Shinya Ikematsu,
Sadatoshi Sakuma
Serial No. : 09/763,586
Conf. No. : 7871
Filed : February 22, 2001
For : Pharmaceutical Compositions For The Prevention And Treatment Of
Atherosclerosis And Restenosis After PTCA

Assistant Commissioner for Patents
Washington, D.C. 20231

ELECTION UNDER 35 USC §121

Sir:

A Petition and Fee for a five-month Extension of Time through and including April 2, 2003,
accompanies this Election.

In response to the written restriction requirement dated October 2, 2002, the applicants hereby elect to prosecute the Group I claims, i.e. claims 1-4 and 6, drawn to pharmaceutical compositions comprising inhibitors of midkine.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

Respectfully submitted,



David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Address : 2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

DRS/la

Attachment: Petition and Fee for Extension of Time